7th Annual Generic Drugs Summit

Online registration for this event has not yet opened. If you wish to register for this or any IIR event, please contact our Customer Service department at 888-670-8200.

Thanks to all of our event sponsors, exhibitors, and media partners for their contributions to this event!

Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200

Need Technical Assistance With this Website?
Send an email to IIR's Web Department

Home»Events»7th Annual Generic Drugs...Event Overview»2006 Agenda Day One

7th Annual Generic Drugs Summit

when and where

September 27 - 29, 2006 | The Fairmont, Washington , DC

doc title

2006 Agenda Day One

Thursday, September 28, 2006

This is just a snapshot of Day One.
For complete details please download our conference brochure.

7:00	*Registration and Morning Coffee*
8:00	Co-Chairperson's Opening Remarks Shashank Upadhye Vice President – Head of Intellectual Property SANDOZ US, Novartis Corporate Intellectual Property Department
8:15	KEYNOTE: Update on the Hatch-Waxman Reform The Honorable Henry A. Waxman, MEMBER OF CONGRESS UNITED STATES, CALIFORNIA DISTRICT 30
9:15	Federal Trade Commission Actions Involving Generic Drugs Markus H. Meier, Assistant Director, Healthcare Division, Bureau of Competition, FEDERAL TRADE COMMISSION
10:15	Morning Refreshment and Networking Break
10:45	Brand-Generic Settlements: Drug Pacts Delaying Generics from Market Entry Moderator: Steve Maddox, Partner, FOLEY AND LARDNER Panelists: Markus H. Meier, Assistant Director, Healthcare Division, Bureau of Competition, FEDERAL TRADE COMMISSION Meredyth Smith Andrus, Attorney, Health Care Division, Bureau of Competition, FEDERAL TRADE COMMISSION David Balto, Partner, ROBINS, KAPLAN, MILLER & CIRESI LLP
12:00	Luncheon for Delegates and Speakers

Track A:
Intellectual Property & Legal Issues

Track B:
Business Development

1:15 Trends and Tactics in Litigating and Settling ANDA Proceedings

Steve Maddox, Partner,
FOLEY AND LARDNER

1:15 Predicting the Next Wave: Changes in the Global Generics Sector Implications for Manufacturers and Investors

Jean Hoffman, President,
Q STREET ADVISORS, INC. & PUTNEY, INC.

2:00 Inequitable Conduct – Strategies for Invalidating The Branded Pharma Patents

Shashank Upadhye, Vice President – Head Of Intellectual Property,
SANDOZ US, Novartis Corporate Intellectual Property Department

2:00 2006 US Strategic Management Review: Trends, Issues, Outlook

Diana Conmy, Corporate Director,
Market Insights, IMS HEALTH

2:45 Global Actions Dramatically Impacting the Delivery of Affordable, Quality Pharmaceuticals for Two Thirds of the World's Population

William F. Haddad Chairman and CEO
BIOGENERICS

2:45 Generic Pharma's Race to Merge and Acquire: Critical Issues to Consider when Entering into an M&A Transaction

Moderated by:

Steven Dubow, Partner,
BLANK ROME LLP

David F. Mulder, Senior Vice President, Director of Business Development and Strategy,
MAYNE PHARMA

Art Koch,Senior Vice President and Chief Financial Officer,
IMPAX LABORATORIES

H. Keeto Sabharwal, Partner,
BLANK ROME LLP

Tim Hillman,Vice President and Director of Business Development,
MAYNE PHARMA

James R. Staiger, Partner,
BLANK ROME LLP

3:30

Refreshment and Networking Break

4:00

The Follow-On Biologics Struggle Continues: The 2006 Update with Views on the Scientific, Regulatory, Economic and Legal Dynamics Impacting the Debate

Moderator:
William Haddad, Chairman and CEO,
BIOGENERICS

Panelists:
Suzanne M. Sensabaugh, Vice President, Biopharmaceutical Development, MDS Pharma
MDS PHARMA

David Rosen, Partner,
FOLEY & LARDNER

Henry Grabowski, PhD, Professor of Economics,Fuqua School of Business,
DUKE UNIVERSITY

Robert G. Bell, PhD, President/Owner
DRUG AND BIOTECHNOLOGY DEVELOPMENT, LLC

5:45

Day One Concludes